Luminex

CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.

Clinicians identifying and treating S. aureus bloodstream infections reduced the median length of stay by 5.6 days and hospital cost by $13,341 per patient after using Luminex's assay.

The firm placed 65 sample-to-answer systems under contract in the second quarter compared to 35 systems in the prior-year quarter.

Though the Dow, the Nasdaq, and the Nasdaq Biotechnology Index all rose in May, they were outperformed by the GenomeWeb Index.

Total sample-to-answer molecular product revenue for the first quarter of 2018 was $16.5 million, representing 49 percent growth.

The Dublin-based company also aims to raise up to €5 million this year to support additions to its R&D and sales and marketing teams.

Luminex said that its MDx sample-to-answer portfolio grew 31 percent over the prior-year quarter and generated $12.9 million.

Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.

Natera outlined its work with pharmaceutical firms to use the Signatera assay, while Luminex was bullish about its growing molecular diagnostics business.

Pages

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.